Surrozen (NASDAQ:SRZN) Trading Down 1.4% - What's Next?

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) was down 1.4% on Tuesday . The stock traded as low as $8.84 and last traded at $8.89. Approximately 8,982 shares changed hands during trading, a decline of 58% from the average daily volume of 21,600 shares. The stock had previously closed at $9.02.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and issued a $32.00 price objective on shares of Surrozen in a research report on Monday, May 12th.

Surrozen Stock Up 8.0%

The stock has a market capitalization of $77.21 million, a PE ratio of -0.36 and a beta of 0.57. The firm's fifty day moving average is $8.89 and its 200-day moving average is $10.52.

Surrozen (NASDAQ:SRZN - Get Free Report) last issued its earnings results on Friday, May 9th. The company reported ($3.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.09) by ($2.04). The firm had revenue of $0.98 million during the quarter. On average, analysts expect that Surrozen, Inc. will post -8.49 EPS for the current year.

Institutional Investors Weigh In On Surrozen

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in shares of Surrozen by 26.1% in the 4th quarter. Geode Capital Management LLC now owns 22,391 shares of the company's stock valued at $321,000 after purchasing an additional 4,630 shares in the last quarter. Heights Capital Management Inc. purchased a new stake in Surrozen during the first quarter worth about $524,000. Trustees of Columbia University in the City of New York acquired a new position in Surrozen during the fourth quarter worth about $688,000. Adage Capital Partners GP L.L.C. purchased a new position in Surrozen in the fourth quarter valued at about $928,000. Finally, Regents of The University of California purchased a new position in Surrozen in the fourth quarter valued at about $1,912,000. Institutional investors and hedge funds own 66.57% of the company's stock.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.